XA gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer

Cell

Volumn 154, Issue 5, 2013, Pages

  Chang, Kai Hsiung ^a,b,c   Li, Rui ^c   Kuri, Barbara ^a,b   Lotan, Yair ^d   Roehrborn, Claus G ^d   Liu, Jiayan ^f   Vessella, Robert ^g   Nelson, Peter S ^g,h   Kapur, Payal ^d   Guo, Xiaofeng ^e   Mirzaei, Hamid ^e   Auchus, Richard J ^f   Sharifi, Nima ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; 3BETA HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANDROSTANOLONE; PRASTERONE; UNCLASSIFIED DRUG;

ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SINGLE NUCLEOTIDE POLYMORPHISM; UBIQUITINATION;

EID: 84883367616     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2013.07.029     Document Type: Article

References (40)

1. G. Attard, C.S. Cooper, and J.S. de Bono Steroid hormone receptors in prostate cancer: a hard habit to break? Cancer Cell 16 2009 458 462
2. G. Attard, A.H. Reid, R.J. Auchus, B.A. Hughes, A.M. Cassidy, E. Thompson, N.B. Oommen, E. Folkerd, M. Dowsett, W. Arlt, and J.S. de Bono Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer J. Clin. Endocrinol. Metab. 97 2012 507 516
3. S.E. Barrie, G.A. Potter, P.M. Goddard, B.P. Haynes, M. Dowsett, and M. Jarman Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase) J. Steroid Biochem. Mol. Biol. 50 1994 267 273
4. K.H. Chang, and N. Sharifi Prostate cancer-from steroid transformations to clinical translation Nat. Rev. Urol. 9 2012 721 724
5. B.L. Chang, S.L. Zheng, G.A. Hawkins, S.D. Isaacs, K.E. Wiley, A. Turner, J.D. Carpten, E.R. Bleecker, P.C. Walsh, and J.M. Trent Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility Cancer Res. 62 2002 1784 1789
6. K.H. Chang, R. Li, M. Papari-Zareei, L. Watumull, Y.D. Zhao, R.J. Auchus, and N. Sharifi Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer Proc. Natl. Acad. Sci. USA 108 2011 13728 13733
7. P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio BRIM-3 Study Group Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 364 2011 2507 2516
8. J.M. Cunningham, S.J. Hebbring, S.K. McDonnell, M.S. Cicek, G.B. Christensen, L. Wang, S.J. Jacobsen, J.R. Cerhan, M.L. Blute, D.J. Schaid, and S.N. Thibodeau Evaluation of genetic variations in the androgen and estrogen metabolic pathways as risk factors for sporadic and familial prostate cancer Cancer Epidemiol. Biomarkers Prev. 16 2007 969 978
9. J.S. de Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K.N. Chi, R.J. Jones, O.B. Goodman Jr., F. Saad COU-AA-301 Investigators Abiraterone and increased survival in metastatic prostate cancer N. Engl. J. Med. 364 2011 1995 2005
10. K. Evaul, R. Li, M. Papari-Zareei, R.J. Auchus, and N. Sharifi 3β-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer Endocrinology 151 2010 3514 3520
11. J. Geller, J. Albert, D. Loza, S. Geller, W. Stoeltzing, and D. de la Vega DHT concentrations in human prostate cancer tissue J. Clin. Endocrinol. Metab. 46 1978 440 444
12. C. Greenman, P. Stephens, R. Smith, G.L. Dalgliesh, C. Hunter, G. Bignell, H. Davies, J. Teague, A. Butler, and C. Stevens Patterns of somatic mutation in human cancer genomes Nature 446 2007 153 158
13. K.E. Knudsen, and T.M. Penning Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer Trends Endocrinol. Metab. 21 2010 315 324
14. S. Kobayashi, T.J. Boggon, T. Dayaram, P.A. Jänne, O. Kocher, M. Meyerson, B.E. Johnson, M.J. Eck, D.G. Tenen, and B. Halmos EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 352 2005 786 792
15. R. Li, K. Evaul, K.K. Sharma, K.-H. Chang, J. Yoshimoto, J. Liu, R.J. Auchus, and N. Sharifi Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer Clin. Cancer Res. 18 2012 3571 3579
16. M.C. Lorence, B.A. Murry, J.M. Trant, and J.I. Mason Human 3 beta-hydroxysteroid dehydrogenase/delta 5 - - 4isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/isomerization of C21 and C19 steroids Endocrinology 126 1990 2493 2498
17. V. Luu-The, A. Bélanger, and F. Labrie Androgen biosynthetic pathways in the human prostate Best Pract. Res. Clin. Endocrinol. Metab. 22 2008 207 221
18. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, and F.G. Haluska Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N. Engl. J. Med. 350 2004 2129 2139
19. R.B. Montgomery, E.A. Mostaghel, R. Vessella, D.L. Hess, T.F. Kalhorn, C.S. Higano, L.D. True, and P.S. Nelson Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res. 68 2008 4447 4454
20. S.E. Ong, B. Blagoev, I. Kratchmarova, D.B. Kristensen, H. Steen, A. Pandey, and M. Mann Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics Mol. Cell. Proteomics 1 2002 376 386
21. T.M. Penning New frontiers in androgen biosynthesis and metabolism Curr. Opin. Endocrinol. Diabetes Obes. 17 2010 233 239
22. H.I. Scher, and C.L. Sawyers Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis J. Clin. Oncol. 23 2005 8253 8261
23. H.I. Scher, K. Fizazi, F. Saad, M.E. Taplin, C.N. Sternberg, K. Miller, R. de Wit, P. Mulders, K.N. Chi, N.D. Shore AFFIRM Investigators Increased survival with enzalutamide in prostate cancer after chemotherapy N. Engl. J. Med. 367 2012 1187 1197
24. N. Sharifi Minireview: Androgen metabolism in castration-resistant prostate cancer Mol. Endocrinol. 27 2013 708 714
25. N. Sharifi, J.L. Gulley, and W.L. Dahut Androgen deprivation therapy for prostate cancer JAMA 294 2005 238 244
26. M. Shimodaira, T. Nakayama, N. Sato, N. Aoi, M. Sato, Y. Izumi, M. Soma, and K. Matsumoto Association of HSD3B1 and HSD3B2 gene polymorphisms with essential hypertension, aldosterone level, and left ventricular structure Eur. J. Endocrinol. 163 2010 671 680
27. J. Simard, M.L. Ricketts, S. Gingras, P. Soucy, F.A. Feltus, and M.H. Melner Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family Endocr. Rev. 26 2005 525 582
28. B.L. Song, N. Sever, and R.A. DeBose-Boyd Gp78, a membrane-anchored ubiquitin ligase, associates with Insig-1 and couples sterol-regulated ubiquitination to degradation of HMG CoA reductase Mol. Cell 19 2005 829 840
29. G. Thomas, K.B. Jacobs, M. Yeager, P. Kraft, S. Wacholder, N. Orr, K. Yu, N. Chatterjee, R. Welch, and A. Hutchinson Multiple loci identified in a genome-wide association study of prostate cancer Nat. Genet. 40 2008 310 315
30. M.A. Titus, M.J. Schell, F.B. Lih, K.B. Tomer, and J.L. Mohler Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer Clin. Cancer Res. 11 2005 4653 4657
31. S.A. Tomlins, D.R. Rhodes, S. Perner, S.M. Dhanasekaran, R. Mehra, X.W. Sun, S. Varambally, X. Cao, J. Tchinda, and R. Kuefer Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648
32. C. Tran, S. Ouk, N.J. Clegg, Y. Chen, P.A. Watson, V. Arora, J. Wongvipat, P.M. Smith-Jones, D. Yoo, and A. Kwon Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 324 2009 787 790
33. Q. Wang, L. Li, and Y. Ye Inhibition of p97-dependent protein degradation by Eeyarestatin I J. Biol. Chem. 283 2008 7445 7454
34. Q. Wang, H. Mora-Jensen, M.A. Weniger, P. Perez-Galan, C. Wolford, T. Hai, D. Ron, W. Chen, W. Trenkle, A. Wiestner, and Y. Ye ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells Proc. Natl. Acad. Sci. USA 106 2009 2200 2205
35. X. Yuan, and S.P. Balk Mechanisms mediating androgen receptor reactivation after castration Urol. Oncol. 27 2009 36 41
36. J. Bloom, V. Amador, F. Bartolini, G. DeMartino, and M. Pagano Proteasome-mediated degradation of p21 via N-terminal ubiquitinylation Cell 115 2003 71 82
37. J. Cox, and M. Mann MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification Nat. Biotechnol. 26 2008 1367 1372
38. C.E. Kan, J.T. Patton, G.R. Stark, and M.W. Jackson p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21 Cancer Res. 67 2007 9862 9868
39. M.S. Rodriguez, J.M. Desterro, S. Lain, C.A. Midgley, D.P. Lane, and R.T. Hay SUMO-1 modification activates the transcriptional response of p53 EMBO J. 18 1999 6455 6461
40. D.P. Xirodimas, M.K. Saville, J.C. Bourdon, R.T. Hay, and D.P. Lane Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity Cell 118 2004 83 97